Licudan, Rey .

HRN: 28-69-89  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/17/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/17/2026
03/24/2026
IV
2.25G
Q8
CRBSI
Checking Initial Appropriateness 

 Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines